Clinical Trials Arena June 18, 2025
At BIO 2025, FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability to function by emphasising that they did not affect scientific reviewers or inspectors, at an ongoing industry meeting.
“I’m proud to report that we’re on track to meet all the newfound targets, and that morale is good and improving at the agency,” said Makary. He said the cuts concerned redundancies caused by certain departments having their own legislative, communication staff, and in other departments like HR and procurement – which constitute about 10% of the entire agency...
Today's Sponsors
Today's Sponsor